



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Lenervimab

Cat. No.:	HY-P99693
CAS No.:	2055006-79-4
Target:	HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Lenervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenervimab can be used for research of hepatitis B virus infection <sup>[1][2]</sup> .								
<b>In Vitro</b>	<p>Lenervimab (1 nM-1 <math>\mu</math>M, 16 h) inhibits HBV infection in HepG2-NTCP cells infected with HBV<sup>[1]</sup>. Lenervimab recognizes many viral genotypes and clinical variants of HBV infection<sup>[1]</sup>. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot Analysis<sup>[1]</sup></p> <table><tr><td>Cell Line:</td><td>HepG2-NTCP cells infected with HBV</td></tr><tr><td>Concentration:</td><td>1 nM-1 <math>\mu</math>M</td></tr><tr><td>Incubation Time:</td><td>16 h</td></tr><tr><td>Result:</td><td>Inhibited viral expression of the surface antigen HBsAg (hepatitis B virus surface antigen) and the core protein HBCAg.</td></tr></table>	Cell Line:	HepG2-NTCP cells infected with HBV	Concentration:	1 nM-1 $\mu$ M	Incubation Time:	16 h	Result:	Inhibited viral expression of the surface antigen HBsAg (hepatitis B virus surface antigen) and the core protein HBCAg.
Cell Line:	HepG2-NTCP cells infected with HBV								
Concentration:	1 nM-1 $\mu$ M								
Incubation Time:	16 h								
Result:	Inhibited viral expression of the surface antigen HBsAg (hepatitis B virus surface antigen) and the core protein HBCAg.								

### REFERENCES

[1]. Jeong GU, et al. A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants. PLoS One. 2020 Aug 13;15(8):e0236704.

[2]. Lee HW, et al. Efficacy of Lenervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2020 Dec;18(13):3043-3045.e1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA